Current status of radionuclide therapies in metastatic castration-resistant prostate cancer
Therapeutic Advances in Medical Oncology · 2025-09 · 17
DOI: 10.1177/17588359251379739 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 02.10.2025. Verfasst von Xin Fei und 6 weiteren Autor:innen. Beteiligte Einrichtung: Health Science Center, Ningbo University, Ningbo, Zhejiang, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ningbo Clinical Research Center for Urological Disease, Ningbo Top Medical and Health Research Program, 2025 Key Research and Development Plan.
Abstract (Originalsprache)
The treatment of metastatic castration-resistant prostate cancer (mCRPC) remains a huge challenge. Newer radionuclides, such as 223 Ra, 177 Lu, 225 Ac, etc., have shown efficacy in alleviating cancer-related pain and also in enhancing the prognosis of mCRPC patients. These novel radionuclides have emerged as important weapons in the treatment of mCRPC. This article reviews recent advances and key clinical trials in various radionuclides and their combinations in the application for treating mCRPC. Further directions of this new treatment strategy are also discussed in this review.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Health Science Center, Ningbo University, Ningbo, Zhejiang, China.
- Department of General Surgery, Yuyao People's Hospital, Ningbo, Zhejiang, China.
- Department of Pharmacy, The First Affiliated Hospital of Ningbo University, Ningbo Zhejiang, China.
- Department of Nuclear Medicine, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang 315000, China.
- Comprehensive Genitourinary Cancer Center, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang 315000, China.
- Translational Research Laboratory for Urology, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China.
Förderung
- Ningbo Clinical Research Center for Urological Disease
- Ningbo Top Medical and Health Research Program
- 2025 Key Research and Development Plan
Zitieren
APA
Fei, X., Huang, R. D., Zhou, X., Ye, S. J., Nan, N., Wang, K. J., & Ma, Q. (2025). Current status of radionuclide therapies in metastatic castration-resistant prostate cancer. Therapeutic Advances in Medical Oncology, 17. https://doi.org/10.1177/17588359251379739
Vancouver
Fei X, Huang RD, Zhou X, Ye SJ, Nan N, Wang KJ, et al. Current status of radionuclide therapies in metastatic castration-resistant prostate cancer. Therapeutic Advances in Medical Oncology. 2025;17. doi:10.1177/17588359251379739
BibTeX
@article{Fei2025,
author = {Fei, Xin and Huang, Rui-Da and Zhou, Xuan and Ye, Shi-Jie and Nan, Nan and Wang, Ke-Jie and Ma, Qi},
title = {Current status of radionuclide therapies in metastatic castration-resistant prostate cancer},
journal = {Therapeutic Advances in Medical Oncology},
year = {2025},
volume = {17},
doi = {10.1177/17588359251379739}
}
EUVIMED